Supplemental Table. The summary of findings tables for primary outcomes using GRADE evidence

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Probiotic for Pregnant Women** | | | | | | |
| **Patient or population:** Pregnant Women **Intervention:** Probiotic | | | | | | |
| **Outcomes** | **Illustrative comparative risks\* (95% CI)** | | **Relative effect (95% CI)** | **No of Participants (studies)** | **Quality of the evidence (GRADE)** | **Comments** |
| Assumed risk | Corresponding risk |
|  | **Control** | **Probiotic** |  |  |  |  |
| **Atopic eczem** | **322 per 1000** | **219 per 1000** (187 to 261) | **RR 0.68**  (0.58 to 0.81) | 1805 (7 studies) | ⊕⊕⊕⊝ **moderate**1 |  |
| **Eczema** | **509 per 1000** | **402 per 1000** (346 to 463) | **RR 0.79**  (0.68 to 0.91) | 1701 (7 studies) | ⊕⊕⊕⊝ **moderate**2 |  |
| **Allergic disease** | **377 per 1000** | **347 per 1000** (298 to 407) | **RR 0.92**  (0.79 to 1.08) | 1168 (5 studies) | ⊕⊕⊝⊝ **low**2,3 |  |
| **IgE-associated allergic disease** | **184 per 1000** | **181 per 1000** (101 to 321) | **RR 0.98**  (0.55 to 1.74) | 1104 (3 studies) | ⊕⊕⊝⊝ **low**2,4 |  |
| **Asthma** | **135 per 1000** | **117 per 1000** (77 to 178) | **RR 0.87**  (0.57 to 1.32) | 630 (3 studies) | ⊕⊝⊝⊝ **very low**1,3,5 |  |
| **Sensitization** | **415 per 1000** | **365 per 1000** (316 to 423) | **RR 0.88**  (0.76 to 1.02) | 1240 (7 studies) | ⊕⊕⊕⊝ **moderate**2 |  |
| **Cesarean section** | **328 per 1000** | **295 per 1000** (263 to 335) | **RR 0.90**  (0.8 to 1.02) | 2110 (14 studies) | ⊕⊕⊕⊝ **moderate**1 |  |
| **Gestational age** | The mean gestational age in the control groups was **0.11 month** | The mean gestational age in the intervention groups was **0.09 higher** (0.04 to 0.15 higher) |  | 1292 (9 studies) | ⊕⊕⊕⊝ **moderate**1 |  |
| **birth weight** | The mean birth weight in the control groups was **0.006 Kg** | The mean birth weight in the intervention groups was **0.01 higher** (0.05 lower to 0.07 higher) |  | 2483 (13 studies) | ⊕⊕⊝⊝ **low**1,6 |  |

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  
**CI:** Confidence interval; **RR:** Risk ratio;

GRADE Working Group grades of evidence  
**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.   
**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
**Very low quality:** We are very uncertain about the estimate.

1 The baseline characteristics between groups were balanced, whereas the results might affect by the information bias  
2 The baseline characteristics between groups were relative good (except 1 study)  
3 Results is different from evidence regarding the outcome  
4 moderate heterogeneity  
5 Studies include relatively few patients.  
6 High heterogeneity